The use of T-cell engaging antibodies for acute myeloid leukemia (AML) treatment is in the very early stages. In this interview, Marion Subklewe, MD, of the University of Munich, Munich, Germany, highlights the importance of examining the T-cell engaging antibody constructs that are currently being used for acute lymphoblastic leukemia treatment and applying the lessons learnt in this setting to AML. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
T-cell engaging antibodies: what lessons have we learnt?
